Published in J Am Coll Cardiol on May 21, 2003
A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell (1990) 5.77
Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest (1975) 5.72
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol (2001) 2.83
Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet (2000) 2.57
Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet (2001) 2.56
31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation (1998) 2.06
Cardiac disease in myotonic dystrophy. Cardiovasc Res (1997) 1.98
Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol (2003) 1.84
Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2000) 1.72
Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol (2002) 1.47
Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis (Review). Int J Mol Med (2001) 0.94
An increase in the myocardial PCr/ATP ratio in GLUT4 null mice. FASEB J (2002) 0.91
Myocardial energetics in cardiac hypertrophy. Clin Exp Pharmacol Physiol (2002) 0.90
31P MR spectroscopy in hypertrophic cardiomyopathy: comparison with Tl-201 myocardial perfusion imaging. Am Heart J (1993) 0.83
Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy. J Am Coll Cardiol (2000) 0.83
31P nuclear magnetic resonance spectroscopy: a noninvasive tool to monitor metabolic abnormalities in left ventricular hypertrophy in human. Am J Cardiol (1999) 0.78
Proton-decoupled myocardial 31P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy. Am J Cardiol (1997) 0.78
Cardiovascular Complications of Neuromuscular Disorders. Curr Treat Options Cardiovasc Med (2002) 0.78
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol (2013) 4.81
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest (2006) 3.22
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07
Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol (2009) 2.79
Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet (2009) 2.50
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol (2005) 2.42
Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med (2011) 2.29
Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res (2012) 2.25
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
Surprises of the genome and "personalized" medicine. J Am Coll Cardiol (2008) 1.84
Disruption at the PTCHD1 Locus on Xp22.11 in Autism spectrum disorder and intellectual disability. Sci Transl Med (2010) 1.75
Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A (2003) 1.74
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation (2004) 1.72
Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. J Am Coll Cardiol (2009) 1.64
American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract (2004) 1.59
Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation (2003) 1.56
Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res (2007) 1.51
Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke (2013) 1.51
The cloning, genomic organization and tissue expression profile of the human DLG5 gene. BMC Genomics (2002) 1.50
Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study. Eur J Clin Invest (2010) 1.47
American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract (2004) 1.47
Blood pressure loci identified with a gene-centric array. Am J Hum Genet (2011) 1.44
Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation (2004) 1.35
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet (2012) 1.35
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res (2005) 1.34
Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res (2008) 1.33
Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation (2009) 1.30
Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res (2009) 1.28
Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet (2010) 1.23
Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet (2007) 1.23
PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol (2002) 1.19
The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord (2009) 1.18
Interferon-γ activates expression of p15 and p16 regardless of 9p21.3 coronary artery disease risk genotype. J Am Coll Cardiol (2012) 1.15
Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol (2012) 1.10
Clinical and genetic association of serum ceruloplasmin with cardiovascular risk. Arterioscler Thromb Vasc Biol (2011) 1.10
Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Natl Acad Sci U S A (2005) 1.09
Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol (2014) 1.08
Nature's genetic gradients and the clinical phenotype. Circ Cardiovasc Genet (2009) 1.04
Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. J Mol Cell Cardiol (2004) 1.03
Overlooked and underserved: "action signs" for identifying children with unmet mental health needs. Pediatrics (2011) 1.02
Determinants of cardiac electrophysiological properties in mice. J Interv Card Electrophysiol (2004) 1.02
Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur J Clin Invest (2010) 0.97
Circulating brain-derived neurotrophic factor concentrations and the risk of cardiovascular disease in the community. J Am Heart Assoc (2015) 0.96
Molecular genetic and functional characterization implicate muscle-restricted coiled-coil gene (MURC) as a causal gene for familial dilated cardiomyopathy. Circ Cardiovasc Genet (2011) 0.93
The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies. Hum Genet (2009) 0.92
Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes. BMC Med Genet (2013) 0.90
Arrhythmogenic right ventricular cardiomyopathy is a disease of cardiac stem cells. Curr Opin Cardiol (2010) 0.90
Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity. Cardiovasc Res (2012) 0.90
Phenotypic plasticity of sarcomeric protein mutations. J Am Coll Cardiol (2007) 0.89
Genome-wide association studies of hypertension: have they been fruitful? J Cardiovasc Transl Res (2010) 0.88
Distinct early signaling events resulting from the expression of the PRKAG2 R302Q mutant of AMPK contribute to increased myocardial glycogen. Circ Cardiovasc Genet (2009) 0.88
Genomics in coronary artery disease: past, present and future. Can J Cardiol (2010) 0.88
RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies. PLoS One (2011) 0.87
Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. Am J Physiol Heart Circ Physiol (2013) 0.86
A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy--the Baylor experience (1996-2002). Clin Cardiol (2005) 0.85
Haptoglobin, the good and the bad: is it evidence based? J Am Coll Cardiol (2013) 0.84
Cardiac biomarkers for detection of myocardial infarction: perspectives from past to present. Clin Chem (2004) 0.84
Two chromosome 9p21 haplotype blocks distinguish between coronary artery disease and myocardial infarction risk. Circ Cardiovasc Genet (2013) 0.83
The relationship between obesity and psychiatric disorders across ethnic and racial minority groups in the United States. Eat Behav (2010) 0.83
Personalized cardiovascular medicine: status in 2012. Can J Cardiol (2012) 0.81
Genetic basis and pathogenesis of familial WPW syndrome. Indian Pacing Electrophysiol J (2003) 0.81
Universal health care. Am Heart Hosp J (2007) 0.81
Genomic view of factors leading to plaque instability. Curr Cardiol Rep (2009) 0.80
Creating a genetic risk score for coronary artery disease. Curr Atheroscler Rep (2009) 0.79
A statement on ethics from the HEART Group. JACC Cardiovasc Imaging (2008) 0.78
Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009. Clin Cardiol (2013) 0.78
The cloning, genomic organization and tissue expression profile of the human DLG5 gene: Correction. BMC Genomics (2002) 0.78
Noncoding RNAs in cardiovascular biology and disease. Circ Res (2013) 0.77
FAT10 protects cardiac myocytes against apoptosis. J Mol Cell Cardiol (2013) 0.77
Determinants of plasma vitamin D levels in patients with acute coronary syndromes. Eur J Clin Invest (2011) 0.76
DNA sequence variants and the practice of medicine. Curr Opin Cardiol (2010) 0.76
Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises. Curr Atheroscler Rep (2011) 0.76
Molecular cardiology and genetics in the 21st century--a primer. Curr Probl Cardiol (2006) 0.76
Genome-wide association study of susceptibility alleles for coronary artery disease. Curr Atheroscler Rep (2008) 0.75
PCSK9 inhibition--a new thrust in the prevention of heart disease: genetics does it again. Can J Cardiol (2013) 0.75
Positron molecular imaging, an in vivo glimpse of the genome. J Mol Cell Cardiol (2007) 0.75
Clinical significance of single nucleotide polymorphisms in PCSK9. Curr Atheroscler Rep (2007) 0.75
The number one cause for sudden cardiac death in the young unravels. Cardiology (2009) 0.75
Another chromosomal locus for mitral valve prolapse: close but no cigar. Circulation (2005) 0.75
Transient hypogammaglobulinemia and severe atopic dermatitis: Open-label treatment with immunoglobulin in a case series. Allergy Rhinol (Providence) (2016) 0.75
Echocardiography: a requisite friend of the cardiac geneticist. J Am Soc Echocardiogr (2011) 0.75
Identification of myofilament mutations: its role in the diagnosis and management of hypertrophic cardiomyopathy. Mayo Clin Proc (2008) 0.75
A novel genetic risk factor for myocardial infarction. Curr Atheroscler Rep (2007) 0.75
Reply: The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: more questions than answers? J Am Coll Cardiol (2014) 0.75